{"id":"W4400950647","doi":"10.1007/s40120-024-00647-0","title":"Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)","year":2024,"lang":"en","type":"article","venue":"Neurology and Therapy","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital","funders":"Biogen","keywords":"Natalizumab; Medicine; Dosing; Crossover study; Clinical endpoint; Randomized controlled trial; Anesthesia; Internal medicine; Placebo","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003574209,0.0007574289,0.001090577,0.0002202447,0.0003336148,0.0006350408,0.0005671984,0.0008038484,0.006860987],"category_scores_gemma":[0.002384946,0.0004312758,0.001340716,0.0002319379,0.0006236848,0.0005507478,0.0003466767,0.001531844,0.0009536707],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005590575,"about_ca_system_score_gemma":0.001150925,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004303687,"about_ca_topic_score_gemma":0.0006982447,"domain_scores_codex":[0.9985531,0.0008703095,0.0001077208,0.0001529819,0.0001995399,0.0001163738],"domain_scores_gemma":[0.9980016,0.0005394664,0.0007529396,0.0001497541,0.0001055146,0.0004506045],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8803204,0.05975222,0.0107472,0.0004693337,0.0007046603,0.00004291189,0.0002449341,0.0003263503,0.01698824,0.0001232564,0.001047173,0.0292333],"study_design_scores_gemma":[0.2974506,0.6572891,0.03743967,0.00005461661,0.0004765227,0.0001554297,0.00007651463,0.0008508134,0.004209567,0.0001554411,0.001788035,0.00005357652],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963689,0.0002685815,0.0002852605,0.00009842649,0.00004902683,0.001788769,0.0004930014,0.00001428888,0.0006338024],"genre_scores_gemma":[0.9925345,0.0002653172,0.001453105,0.0003598978,0.00009651999,0.00319644,0.0006388077,0.000008136285,0.001447239],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006860987,"threshold_uncertainty_score":0.02295232,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06544853152701602,"score_gpt":0.3220524910896717,"score_spread":0.2566039595626556,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}